Office of Technology Transfer – University of Michigan

Anti-cancer Screening Test for Inhibitors of HIP1 Function and Specific Inhibitors of HIP1 Function

Technology #2392

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Theodora S. Ross
Managed By
Stefan Koehler
Senior Licensing Specialist, Health Technologies 734-764-4290
Patent Protection
US Patent Pending
“Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells”
Cancer Cell, Volume 3. Page 471. 2003


Existing cancer screening tests are often invasive, expensive, and lack strong diagnostic utility. For example, prostate cancer is typically diagnosed with a digital rectal exam and/or prostate specific antigen (PSA) screening, which has limited sensitivity and specificity. Thus, development of additional serum and tissue cancer biomarkers is needed to supplement current screening methods.


Researchers at the University of Michigan have identified HIP1 (Huntingtin Interacting Protein 1) as a novel oncogene for prostate cancer, colon cancer, lymphoma and brain cancer, thus providing a potential target for screening in tissue samples. The involvement of HIP1 in the clathrin trafficking pathway can also form the basis for a therapeutic target. Researchers have also created HIP1 antibodies and several cell lines that overexpress HIP1 at varying levels, which can be used for a high-throughput screen for therapeutic compounds that target HIP1.

Applications and Advantages


  • Diagnostic kits and screening assays for-nl-development of therapeutic drugs
  • Therapeutics based on gene therapy,-nl-antibody, domain targeting by small molecules-nl-and anti-sense approaches


  • More sensitive and specific and non-invasive-nl-diagnostic and prognostic tests.

Publications: “Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells” Cancer Cell (2003), 3, p. 471

See UM File #2164 and File #3667